In their article entitled, "Metabolic and Structural Effects of Phosphatidylcholine and Deoxycholate Injections on Subcutaneous Fat: A Randomized, Controlled Trial," Reeds et al analyzed the effects of phosphatidylcholine and deoxycholate (PC-DC) treatments on body composition, adipocyte function, and mechanisms responsible for fat loss. Thirteen women were enrolled; only 7 completed the study. This small sample size renders statistically significant calculations virtually impossible.
The authors maintain that PC-DC injections have become increasingly popular. This may be true in Seoul, Korea, where over 6000 vials of Lipobean 1 are injected monthly into human subcutaneous fat for the purpose of fat reduction. However, in many countries around the world, the practice of injection lipolysis has been banned.
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Popularity of these injections in the United States has dwindled, 3 in part due to the lack of a US Food and Drug Administration (FDA)-approved agent and also due to the lack of efficacy in treating larger body regions. 4 The side effects, although not morbid, are unpleasant. Noninvasive treatments such as Liposonix (Solta Medical, Inc, Bothell, Washington) and Tite FX (Invasix, Richmond Hill, Ontario, Canada) 5, 6 offer much more fat reduction without the cholinergic side effects that can be seen with higher-dose PC-DC injections.
Despite the shortcomings of injection lipolysis as currently practiced, there has been a resurgence of interest in the topic, 7 especially in Europe and Asia. There are many reasons for this, including the expansion of the practice of aesthetic medicine and the desire of practitioners who mainly perform injections to have an injectable solution for reduction of protrusions. If aesthetic practitioners can fill hollow regions, they may also want to reduce or take away volume. The ability to do this precisely with an injection would be an excellent addition to the cosmetic injector's options.
The mechanism of action of PC-DC injections has been explored by several investigators, although none employed the breadth of testing presented in this study. The conjecture by Rotunda et al 8 that the detergent effect of sodium deoxycholate was the mechanism of action of the drug was confirmed in a study done by Duncan et al in 2009. 9 In this stem cell study, PC, normally solubilized in DC, was isolated and solubilized in inert mineral oil. Two cytotoxicity assays and 2 lipolytic assays were performed on the differentiated adipocytes. Solutions tested included PC alone, PC50-DC42, 2 concentrations of deoxycholate, the benzyl alcohol preservative, and a saline control. Phosphatidylcholine alone had no cytotoxic or lipolytic effect; the readings were equivalent to the saline control. Deoxycholate had a dose-dependent cytotoxic and lipolytic effect. Benzyl alcohol had no cytotoxic or lipolytic effect. Interestingly, the histologic presence of "crown-like structures" is a marker for adipocyte inflammation and death in metabolic syndrome 10, 11 ; it is not a hallmark specific to injection lipolysis. Apoptosis is present in human adults as a normal occurrence. More than 50 billion cells die an apoptotic death on a daily basis in most adults. 12 The caspase markers measured in this study show a decrease of caspase-3 on both the control side and the treated side at 8 weeks. Caspase-3 levels measure cells killed by this effector enzyme. 13 A low level of caspase-3 would indicate that little to no actual apoptotic cell death had occurred.
Many authors note the presence of cell wall lysis [14] [15] [16] -an event not present with apoptosis-in their histologic evaluation of the tissue reaction to injection lipolysis. The toxic tissue injury caused by PC-DC injections causes an overwhelming oncotic effect. Commonly known as "necrosis," tissue oncosis is caused by an inflammatory event or injury causing loss of cell respiration due to oxygen deprivation. 17 The strong response of swelling, pain, and inflammation-signs of an oncotic reaction-is clear in patients who 18 is a caspase-1-mediated mechanism of cell death that has features of both apoptosis and oncosis. Tissue aspirate may not provide an adequate specimen for apoptosis evaluation; cell distortion-especially of adipocytes-can mask the membrane blebs, pyknotic nuclei, cell shrinkage, and tissue collapse pattern seen with true apoptosis. 19 Although both apoptosis and pyroptosis may be present-and it would have been interesting to see the caspase-1 levels in the present study-the evidence is overwhelming that toxin-induced tissue necrosis is the mechanism of the PC-DC effect.
The detergent effect on cell membranes has been extensively studied by protein chemists. 20 Detergents are amphipathic molecules, having a hydrophilic tail and a hydrophobic head. An ionic detergent such as deoxycholate inserts or "partitions" into the cell membrane and denatures proteins. At a lower dose of deoxycholate, the cell membrane undergoes poration and becomes "leaky." At a higher concentration, the detergent effect causes micelle formation, with subsequent cell wall lysis. 21 The addition of PC to the formula causes liposome formation rather than micelle formation. 22 Histologic effects of PC-DC injections and DC injections have appeared in the literature since 2004. 7 Rotunda et al 8 noted necrosis of adipocytes in porcine tissue, as well as death of skeletal muscle cells. Rose and Morgan 23 noted in his human biopsies that adipocyte necrosis was present at 1 week and 2 weeks following injection. The 30-patient study by Yagima Odo et al 24 showed adipocyte lysis with inflammation and phagocytosis by macrophages. Schuller-Petrovic et al 25 concurred and noted dose-dependent fibroplasia in histologic specimens, as well as muscle loss and necrotic changes in the walls of small blood vessels.
The lack of tissue specificity of the PC-DC injections, or DC injections alone, is a safety concern first raised by Rotunda et al in 2004. 8 Gupta et al 26 performed a tetrazolium bromide assay on different tissue types to assess the cytotoxic effect of PC-DC or DC alone on preadipocytes, fibroblasts, endothelial cells, and muscle cells at 1, 2, and 3 days. The group reported similar kill rates for all cell types, showing nearly 100% cell lysis at 24 hours. Their conclusion was that these compounds act in a "nonspecific manner" and therefore may be unsafe if unintentionally injected in the wrong location.
These changes occur over time, as noted by Duncan and Golitz 27 in a serial histology study performed in 2008. Biopsies were taken at 1 week, 2 weeks, and 8 weeks following patient treatment with a saline control, PC50-DC42, and DC 24 mg/mL alone. The DC solutions showed immediate cell wall lysis with ground substance formation and extensive necrosis at 1 day, with fibrosis at 2 weeks and extensive fibrosis at 8 weeks. In contrast, the onset of cell wall lysis was delayed in the PC-DC specimen and was not visible until 2 weeks postinjection. Inflammatory changes with PC-DC were noted in the fibroseptal region, but no extensive fibrosis was noted.
In that same study, Duncan and Golitz 27 noted that a phenomenon called "necrobiosis" occurred at 8 weeks in the deep reticular dermis of the deoxycholate-injected specimen. The deep layer of the dermis-not initially injected during treatment-was noted to have a bluish cast to the normally pink collagen of the reticular dermal layer. This was accompanied by thickening and sclerosis of the blood vessels, with a similar pattern noted in eccrine glands and hair follicles. These findings, in addition to patient intolerance of injection-associated pain, swelling, and bruising, have led to the reduction in the concentration of PC-DC; in Europe and in Korea, the most commonly injected formula is PC25-DC12.
New uses for injection lipolysis include very small amounts of dilute PC-DC for reduction of facial features such as cheeks, nasolabial folds, marionette "poufs, The magnetic resonance imaging findings by Reeds et al are irrefutable; injections of PC and DC do indeed work for subcutaneous fat reduction. Initially quite popular, these treatments have lost favor due to the pain and downtime associated with the injections, the lack of an FDA-approved drug, and the lack of a tissue-specific response to these injections. As the popularity of aesthetic medicine grows, an increasing number of noncore practitioners will be performing cosmetic injections. Although efficacious, the lack of tissue specificity of PC-DC injections creates a concern regarding long-term safety when the drug is injected by untrained practitioners.
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